Emmaus Life Sciences, Inc. Reports Material Event
Emmaus Life Sciences, Inc. reported that director Jon Kuwahara resigned from its board.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Emmaus Life Sciences, Inc. reported that director Jon Kuwahara resigned from its board. The resignation was dated April 13, 2026 and becomes effective April 15, 2026. The company also identified a cover page interactive data file as Exhibit 104 embedded within the inline XBRL document.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Resignation date: April 13, 2026
Effective resignation date: April 15, 2026
Signature date: April 14, 2026
+1 more
4 metrics
Resignation date
April 13, 2026
Date Jon Kuwahara submitted resignation as director
Effective resignation date
April 15, 2026
Date Jon Kuwahara’s resignation becomes effective
Signature date
April 14, 2026
Date the report was signed by Willis Lee
Exhibit number
104
Cover Page Interactive Data File in inline XBRL
Key Terms
Emerging growth company, Item 5.02, inline XBRL, Exhibit 104
4 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"
Item 5.02 is a specific disclosure category on the U.S. Securities and Exchange Commission’s Form 8‑K that requires public companies to report changes in key personnel and related compensation arrangements. It covers departures and appointments of directors and certain officers, elections of directors, and new or material changes to compensatory agreements for those persons; the company must file a Form 8‑K with the required information and any related exhibits within the SEC’s prescribed reporting timeframe. The item is a rule‑based reporting obligation under U.S. securities law, so its scope and timing follow the SEC’s definitions and deadlines rather than informal usage.
inline XBRL technical
"Cover Page Interactive Data File (embedded within the inline XBRL Document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Exhibit 104 regulatory
"Exhibit Number | | Description 104 | | Cover Page Interactive Data File"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Emmaus Life Sciences (EMMA) announce in this 8-K filing?
Emmaus Life Sciences announced that director Jon Kuwahara resigned from its board. His resignation was dated April 13, 2026 and is effective April 15, 2026. The filing also lists a cover page interactive data file as Exhibit 104 in the inline XBRL document.
When is Jon Kuwahara’s resignation from Emmaus Life Sciences (EMMA) effective?
Jon Kuwahara’s resignation as a director of Emmaus Life Sciences is effective April 15, 2026. The filing states that he resigned on April 13, 2026, with that effective date, providing a brief transition window between the resignation date and effectiveness.
Which item of the 8-K covers the director resignation at Emmaus Life Sciences (EMMA)?
The director resignation is disclosed under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. This item specifically notes that director Jon Kuwahara resigned effective April 15, 2026.
Who signed the Emmaus Life Sciences (EMMA) 8-K reporting the director resignation?
The 8-K was signed on behalf of Emmaus Life Sciences by Willis Lee. The filing identifies Willis Lee as the company’s Chairman and Chief Executive Officer and shows the signature date as April 14, 2026, following the reported resignation date.
What exhibit was included with Emmaus Life Sciences’ (EMMA) 8-K about the director resignation?
The filing lists Exhibit 104 as a cover page interactive data file. It states that this file is embedded within the inline XBRL document, providing structured data representation of the cover page information associated with the 8-K filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates